Frontiers in Pharmacology (Jun 2020)

Pharmacotherapics Advice in Guidelines for COVID-19

  • Zhang-Ren Chen,
  • Ying Zhou,
  • Jin Liu,
  • Hong-Wei Peng,
  • Jian Zhou,
  • Hai-Li Zhong,
  • Li-Li Liu,
  • Ming-Fang Lai,
  • Xiao-Hua Wei,
  • Jin-Hua Wen

DOI
https://doi.org/10.3389/fphar.2020.00950
Journal volume & issue
Vol. 11

Abstract

Read online

Since December 2019 to May 2020, coronavirus disease 2019 (COVID-19) has infected over 6 million people worldwide. Due to its sudden and rapid outbreak, effective treatment for COVID-19 is scarce. Based on national clinical trials of novel treatments, China, Italy, Germany, and other countries and organizations have published multiple guidelines for COVID-19 and advised many medicines, such as chloroquine and tocilizumab. In this paper, we summarize the pharmacotherapy for COVID-19 according to those guidelines, highlight updates of the pharmacotherapy guidelines, and review the efficacy and safety of the indicated anti-COVID-19 drugs.

Keywords